@ftr_investorsFeb 20, 2026 · 1:42 PM

$GRAL Grail is crashing hard 📉😱 The NHS-Galleri trial missed its primary endpoint: no statistically significant reduction in late-stage cancers🎗️ That directly impacts the FDA approval path and reimbursement potential and therefore the growth story https://t.co/GE942EJ7ob

@adamfeuersteinFeb 19, 2026 · 10:51 PM

Key study of $GRAL Grail’s cancer detection test fails in setback for company https://t.co/9KyJPAyZzZ via @matthewherper

@adamfeuersteinFeb 19, 2026 · 9:23 PM

$GRAL NHS-Galeri trial fails. Another blow to $HIMS

@ftr_investorsFeb 4, 2026 · 7:29 PM

$HIMS $GRAL Hims & Hers launched a multi-cancer early detection blood test, giving customers access to GRAIL’s Galleri test, which can screen for 50+ cancers, often before symptoms, via its Labs platform, at a discounted price 🧬🩸 https://t.co/Tm1d6OCZth

@adamfeuersteinOct 18, 2025 · 7:22 PM

Grail $GRAL says new data on multi-cancer screening test show improved performance https://t.co/URX2W6nqUj via @JonathanWosen #ESMO25